Hong Lai Huat (SGX:CTO) bought back 500,000 shares worth SG$41,130 on Thursday, according to a same-day filing with the Singapore Exchange.
The property developer is authorized to buy back around 48.3 million shares under its existing buyback mandate.
Innovent Biologics' (HKG:1801) new drug application for arcotatug tavatecan was accepted by China's National Medical Products Administration and granted priority review, according to a Thursday Hong Kong bourse filing.The application was submitted after an international multi-center phase 3 clinical study of the drug reached the primary endpoint after completing the per-protocol first interim analysis.The drug demonstrated excellent efficacy and a tolerable safety profile in the treatment of advanced gastric cancer.
Super-Dragon Engineering Plastics (SHE:301131) completed its industrial and commercial registration change and received a new business license from the Guangzhou Municipal Administration for Market Regulation.The company specializes in engineering plastics, synthetic resins, bio-based materials and high-performance composites, according to a Thursday filing with the Shenzhen bourse.Shares of the industrial supplies company closed 2% lower Thursday.
Hong Fok (SGX:H30) bought back 198,000 shares in the open market on Thursday for around SG$192,874, according to a same-day after-market filing with the Singapore Exchange.To date, the property investment company has repurchased over 3.6 million shares under its current buyback program.